These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11438833)

  • 1. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
    Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
    Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
    Siders WM; Halloran PJ; Fenton RG
    Cancer Res; 1996 Dec; 56(24):5638-46. PubMed ID: 8971169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
    Vile R; Miller N; Chernajovsky Y; Hart I
    Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
    Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
    Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable overexpression of human HSF-1 in murine cells suggests activation rather than expression of HSF-1 to be the key regulatory step in the heat shock gene expression.
    Mivechi NF; Shi XY; Hahn GM
    J Cell Biochem; 1995 Oct; 59(2):266-80. PubMed ID: 8904320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo targeting of gene expression to melanoma cells.
    Vile RG; Hart IR
    Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
    Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
    J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock factor regulates VDUP1 gene expression.
    Kim KY; Shin SM; Kim JK; Paik SG; Yang Y; Choi I
    Biochem Biophys Res Commun; 2004 Mar; 315(2):369-75. PubMed ID: 14766217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat-directed gene targeting of adenoviral vectors to tumor cells.
    Brade AM; Ngo D; Szmitko P; Li PX; Liu FF; Klamut HJ
    Cancer Gene Ther; 2000 Dec; 7(12):1566-74. PubMed ID: 11228535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
    Cao G; Zhang X; He X; Chen Q; Qi Z
    In Vivo; 1999; 13(2):181-7. PubMed ID: 10363176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy.
    Ingram N; Porter CD
    Gene Ther; 2005 Jul; 12(13):1058-69. PubMed ID: 15800661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control.
    Nettelbeck DM; Jérôme V; Müller R
    Gene Ther; 1999 Jul; 6(7):1276-81. PubMed ID: 10455436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression.
    Shiraishi K; Yamasaki K; Nanba D; Inoue H; Hanakawa Y; Shirakata Y; Hashimoto K; Higashiyama S
    Oncogene; 2007 Jan; 26(3):339-48. PubMed ID: 16862184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
    Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
    Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short and highly efficient synthetic promoters for melanoma-specific gene expression.
    Martinelli R; De Simone V
    FEBS Lett; 2005 Jan; 579(1):153-6. PubMed ID: 15620705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of gene regulatory elements for selective gene expression in human melanoma cells.
    Artuc M; Nürnberg W; Czarnetzki BM; Schadendorf D
    Biochem Biophys Res Commun; 1995 Aug; 213(2):699-705. PubMed ID: 7646526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity.
    Richardson TB; Kaspers J; Porter CD
    Gene Ther; 2004 May; 11(9):775-83. PubMed ID: 14999228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock transcription factor (Hsf)-4b recruits Brg1 during the G1 phase of the cell cycle and regulates the expression of heat shock proteins.
    Tu N; Hu Y; Mivechi NF
    J Cell Biochem; 2006 Aug; 98(6):1528-42. PubMed ID: 16552721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Gene Ther; 2006 Aug; 13(16):1235-43. PubMed ID: 16617300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.